Anika Therapeutics Inc Revenue Growth Rates (ANIK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Anika Therapeutics Inc   (NASDAQ: ANIK)
 

ANIK's Revenue Growth by Quarter and Year

Anika Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ANIK Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 32.61
1st Quarter March 29.00
FY 61.61

ANIKs Annual Revenue
Anika Therapeutics Inc 's Revenue in the fiscal year 2025 $ 112.81 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2024 $ 119.00 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2023 $ 166.09 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2022 $ 156.24 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2021 $ 147.79 millions




ANIK Revenue second quarter 2026 Y/Y Growth Comment
Anika Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue increase of 19.19% year on year, to $ 32.61 millions.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 64 other companies have achieved higher Revenue growth. While Anika Therapeutics Inc ' s Revenue growth of 19.19% ranks overall at the positon no. 1072 in the second quarter 2026.


ANIK Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - 9.16 %
3rd Quarter September - -28.25 % -6.11 % 1.69 %
2nd Quarter June 19.19 % -33.87 % -5.91 % 10.87 %
1st Quarter March 12.93 % -35.2 % 4.51 % 3.35 %
FY   - -4.53 % -28.86 % -

Financial Statements
Anika Therapeutics Inc 's second quarter 2026 Revenue $ 32.61 millions ANIK's Income Statement
Anika Therapeutics Inc 's second quarter 2025 Revenue $ 27.36 millions Quarterly ANIK's Income Statement


ANIK Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 16.68 % - 5.64 %
3rd Quarter September - 0.8 % -7.08 % -6.89 %
2nd Quarter June 12.45 % 6.54 % 4.39 % 15.95 %
1st Quarter March -9.88 % - -8.37 % -4.29 %
FY (Year on Year)   - -4.53 % -28.86 % -


Back to ANIK Growth rate Comparisons >> Back to ANIK Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #65
Healthcare Sector #212
Overall #1072

Revenue Y/Y Growth Statistics
High Average Low
123.06 % 8.19 % -54.37 %
(Dec 31 2014)   (Sep 30 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #65
Healthcare Sector #212
Overall #1072
Revenue Y/Y Growth Statistics
High Average Low
123.06 % 8.19 % -54.37 %
(Dec 31 2014)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Anika Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
60.04 % 4.39 % -33.26 %
(Mar 31 2014)  


ANIK's II. Quarter Q/Q Revenue Comment
Anika Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.45%, to $ 32.61 millions, from $29.00 millions in the first quarter.
ANIK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Anika Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 715.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #119
Overall #715
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #119
Overall #715
Revenue Q/Q Growth Statistics
High Average Low
60.04 % 4.39 % -33.26 %
(Mar 31 2014)  


ANIK's II. Quarter Q/Q Revenue Comment
Anika Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 12.45%, to $ 32.61 millions, from $29.00 millions in the first quarter.
ANIK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Anika Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 715.


Anika Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 121.37 $ 116.12 $ 112.81 $ 79.34 $ 90.19
Y / Y Revenue Growth (TTM) 34.57 % 11.45 % -4.52 % -51.23 % -45.4 %
Year on Year Revenue Growth Overall Ranking # 3617 # 762 # 2018 # 1450 # 1665
Seqeuential Revenue Change (TTM) 4.52 % 2.94 % 42.19 % -12.04 % -13.44 %
Seq. Revenue Growth (TTM) Overall Ranking # 3298 # 755 # 1828 # 1570 # 1956


Cumulative Revenue growth Comment
Anika Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.57% year on year, to $ 121 millions if the fiscal year would have ended in Jun 30 2026.
Anika Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 5.58% and higher than 11.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.52 % from $116.12 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5.58%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 4.52 % increase from $116.12 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 492 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 762 to 3617.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 154
Healthcare Sector # 493
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
40.64 %
 5.58 %
-51.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 154
Sector # 439
S&P 500 # 3298
Cumulative Revenue growth Comment
Anika Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.57% year on year, to $ 121 millions if the fiscal year would have ended in Jun 30 2026.
Anika Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 5.58% and higher than 11.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.52 % from $116.12 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5.58%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 4.52 % increase from $116.12 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 492 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 762 to 3617.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 154
Healthcare Sector # 493
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
40.64 %
5.58 %
-51.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 154
Sector # 439
S&P 500 # 3298




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ANIK's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions


About Anika Therapeutics Inc Revenue Growth Rates (ANIK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Anika Therapeutics Inc (CIK 898437).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001171843-26-005012
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Anika Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.